Edwards Lifesciences financials
$88.08+1.44%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B | $4.39B | $4.35B | $3.72B | $3.44B | $2.96B |
| Gross profit | $4.73B | $4.32B | $4.03B | $3.74B | $3.98B | $3.31B | $3.23B | $2.78B | $2.56B | $2.17B |
| Gross margin | 78.0% | 79.5% | 80.5% | 83.8% | 76.1% | 75.4% | 74.4% | 74.8% | 74.5% | 73.1% |
| Operating income | $1.20B | $1.38B | $1.31B | $1.50B | $1.69B | $897.6M | $1.15B | $748.2M | $1.09B | $751.2M |
| Net income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B | $823.4M | $1.05B | $722.2M | $583.6M | $569.5M |
| Net margin | 17.7% | 76.7% | 28.0% | 34.1% | 28.7% | 18.8% | 24.1% | 19.4% | 17.0% | 19.2% |
| Diluted EPS | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 | $1.30 | $1.64 | $1.13 | $0.90 | $0.87 |
| EBITDA | $1.74B | $1.64B | $1.66B | $1.68B | $1.85B | $1.45B | $1.33B | $1.15B | $1.10B | $890.6M |
| Operating cash flow | $1.60B | $542.3M | $895.8M | $1.22B | $1.73B | $1.01B | $1.18B | $931.8M | $1.01B | $703.3M |
| Free cash flow | $1.33B | $289.9M | $642.8M | $973.6M | $1.41B | $606.7M | $921.7M | $693.1M | $842.5M | $527.2M |
| Diluted shares | 585.8M | 599.3M | 609.4M | 624.2M | 631.2M | 631.9M | 636.7M | 640.9M | 647.7M | 653.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.94B | $3.05B | $1.13B | $769.0M | $862.8M | $1.18B |
| Short-term investments | $1.29B | $930.7M | $500.5M | $446.3M | $604.0M | $219.4M |
| Total debt | $598.3M | $597.7M | $597.0M | $596.3M | $595.7M | $595.0M |
| Total assets | $13.70B | $13.06B | $9.36B | $8.29B | $8.50B | $7.24B |
| Total liabilities | $3.36B | $2.99B | $2.64B | $2.49B | $2.67B | $2.66B |
| Shareholders' equity | $10.34B | $10.06B | $6.72B | $5.81B | $5.84B | $4.57B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology